Steven Reiss

Array ( [id] => 20335288 [patent_doc_number] => 20250339408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => TREATMENT AND PREVENTION OF BASAL CELL CARCINOMA WITH TOPICAL COMPOSITION COMPRISING PATIDEGIB [patent_app_type] => utility [patent_app_number] => 19/266342 [patent_app_country] => US [patent_app_date] => 2025-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19266342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136147 [patent_doc_number] => 20250243191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR AMELIORATION OF CANCER [patent_app_type] => utility [patent_app_number] => 19/179235 [patent_app_country] => US [patent_app_date] => 2025-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27727 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19179235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20031912 [patent_doc_number] => 20250170134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 19/039174 [patent_app_country] => US [patent_app_date] => 2025-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19039174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19890281 [patent_doc_number] => 20250115593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => ROCAGLATE DERIVATIVES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/904487 [patent_app_country] => US [patent_app_date] => 2024-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 444 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18904487 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19631092 [patent_doc_number] => 20240409541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => NK3 MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/800581 [patent_app_country] => US [patent_app_date] => 2024-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 599 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18800581 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554742 [patent_doc_number] => 20240366534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => LASOFOXIFENE TREATMENT OF BREAST CANCER [patent_app_type] => utility [patent_app_number] => 18/764274 [patent_app_country] => US [patent_app_date] => 2024-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19593117 [patent_doc_number] => 12150935 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-11-26 [patent_title] => 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer [patent_app_type] => utility [patent_app_number] => 18/636905 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 7373 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18636905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202722 [patent_doc_number] => 20240174621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => METHYLQUINAZOLINONE DERIVATIVES [patent_app_type] => utility [patent_app_number] => 18/525536 [patent_app_country] => US [patent_app_date] => 2023-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18525536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127424 [patent_doc_number] => 20240132777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => DYES FOR NUCLEIC ACID DETECTION [patent_app_type] => utility [patent_app_number] => 18/482816 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4238 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19579859 [patent_doc_number] => 12145955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-19 [patent_title] => Cyclic azastannane and cyclic oxostannane compounds and methods for preparation thereof [patent_app_type] => utility [patent_app_number] => 18/373404 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5596 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18373404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157630 [patent_doc_number] => 20240150337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT [patent_app_type] => utility [patent_app_number] => 18/474027 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18474027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111172 [patent_doc_number] => 20240122922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors [patent_app_type] => utility [patent_app_number] => 18/473540 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18473540 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157630 [patent_doc_number] => 20240150337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT [patent_app_type] => utility [patent_app_number] => 18/474027 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18474027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556387 [patent_doc_number] => 20240368179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => IMIDE-BASED MODULATORS OF PROTEOLYSIS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/473802 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18473802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018873 [patent_doc_number] => 20240075044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => CO-PROCESSED PRE-FORMULATED EXCIPIENT COMPOSITION FOR POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS [patent_app_type] => utility [patent_app_number] => 18/241260 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18241260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018873 [patent_doc_number] => 20240075044 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => CO-PROCESSED PRE-FORMULATED EXCIPIENT COMPOSITION FOR POORLY SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS [patent_app_type] => utility [patent_app_number] => 18/241260 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18241260 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096330 [patent_doc_number] => 20240115557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/361352 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096330 [patent_doc_number] => 20240115557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/361352 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096330 [patent_doc_number] => 20240115557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => INHIBITORS OF RNA-GUIDED NUCLEASES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/361352 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18922896 [patent_doc_number] => 20240025900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => TETRACYCLIC COMPOUNDS AS DGK INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/222662 [patent_app_country] => US [patent_app_date] => 2023-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 5903 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18222662 [rel_patent_id] =>[rel_patent_doc_number] =>)